Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 134 of 5804
-
Less radiation for breast cancer? a trial tests a smarter, response-based approach
Disease control Not yet recruitingProspective Comparative Study of Response-Adapted De-escalation of Regional Nodal Irradiation in Initially Node Positive Breast Cancer Patients with Pathological Nodal Complete Response After Neoadjuvant Therapy
Phase: NA • Sponsor: Aya Ahmed Sayed • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a daily cannabinoid pill shield Athletes' brains from concussion?
Prevention Recruiting nowThe goal of this double-blind, placebo-controlled, cross over study is to learn about the neuroprotective properties of a broad-spectrum cannabinoid formulation in normal healthy adults engaged in elite contact sport competition. The main question it aims to answer : • Is the b…
Phase: PHASE2 • Sponsor: University of Regina • Aim: Prevention
Last updated Jul 23, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: Rina-S trial launches
Disease control Not yet recruitingThe purpose of this Chinese extension study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could …
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo therapy aims to boost remission in tough rectal cancer
Disease control Not yet recruitingThis study aims to observe and evaluate the efficacy and safety of moderately hypofractionated radiotherapy combined with chemotherapy and immunotherapy, compared with conventional neoadjuvant chemoradiotherapy, in patients with high-risk locally advanced colorectal cancer.
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could less be more? bladder cancer trial tests stopping immunotherapy after tumors vanish
Disease control Not yet recruitingPatients with extensive transurethrally unresectable very-high-risk non-muscle-invasive bladder cancer (NMIBC) may achieve a tumor-free status after systemic immunotherapy-based bladder-sparing treatment combined with transurethral resection of bladder tumor (TURBT). However, the…
Phase: PHASE2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail aims to shrink rectal tumors and avoid colostomy
Disease control OngoingTo observe and evaluate the efficacy and safety of neoadjuvant long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib Mesylate in the treatment of locally advanced rectal cancer and low-lying rectal cancer with sphincter-preservation demand.
Phase: PHASE2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug cocktail aims to fight tough stomach cancer
Disease control Recruiting nowThis study is a multicenter, randomized, open-label, controlled Phase III clinical trial aimed at evaluating the efficacy and safety of JS107 combined with toripalimab XELOX versus sintilimab combined with XELOX as first-line treatment for patients with advanced G/GEJ adenocarcin…
Phase: PHASE3 • Sponsor: NingBo Junyan Hongshi Biosciences Co., Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?
Disease control Recruiting nowThis is a single-center, interventional, prospective clinical study. A total of 45 patients aged ≥ 60 years with ECOG PS 0-1 who have histologically confirmed, treatment-naïve, unilateral primary invasive HER-2-positive breast cancer will be enrolled according to predefined inclu…
Phase: PHASE4 • Sponsor: Wen-Ming Cao • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for Tough-to-Treat colorectal cancer: phase 3 trial launches
Disease control Recruiting nowColorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine a…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New pill could ease juvenile arthritis in kids
Disease control Recruiting nowThis is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 18 weeks.
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New Pre-Surgery combo aims to shrink rectal tumors and save the rectum
Disease control Not yet recruitingThis study is for adults with locally advanced rectal cancer that has not spread to distant organs, and is classified as pMMR or MSS (which means it typically does not respond well to immunotherapy alone). The purpose is to see if a new combination of treatments given before surg…
Phase: PHASE2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New cocktail aims to shrink untouchable liver tumors into surgical candidates
Disease control Recruiting nowPatients with hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT) face a poor prognosis and are typically ineligible for surgical resection. This prospective study evaluates a conversion therapy regimen-utilizing a combination of FOLFOX-HAIC, Lenva…
Phase: PHASE2 • Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug duo aims to stop aggressive breast cancer's return
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT) sequential capecitabine versus single-agent capecitabine as adjuvant intensified therapy in patients with high-risk early-stage triple-negative breast cancer (TNBC) without…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for bile duct cancer: experimental drug nanvuranlat in final testing
Disease control Recruiting nowThis study is designed to 1) select a dose regimen for continued development and 2) evaluate nanvuranlat versus Physicians Best Choice (PBC) (FOLFOX, FOLFIRI, or Best Supportive Care (BSC)) in participants aged 18 years and over with BTC. Participants enrolling in Part A the tria…
Phase: PHASE3 • Sponsor: J-Pharma Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Blood test may guide extra chemo to stop colon cancer return
Disease control Recruiting nowPhase III multicentric, open-label, randomized study The main objective is to assess the efficacy on time to disease recurrence (TTR) of treating minimal residual disease diagnosed by the presence of ctDNA after full treatment (surgery + chemotherapy) in stage III or high-risk s…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a menstrual blood test replace surgery for endometriosis diagnosis?
Diagnosis Recruiting nowEndometriosis affects at least 1 in 10 women worldwide and is associated with a diagnostic delay of 5-10 years. Currently, definitive diagnosis requires invasive laparoscopy, which is costly and burdensome for patients. This multicenter diagnostic validation study investigates a…
Sponsor: Diamens FlexCo • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
New hope for Tough-to-Treat colon cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocen…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Stem cell showdown: which transplant best keeps T-Cell cancer at bay?
Disease control Not yet recruitingTo evaluate, through a prospective multicenter observational study, autologous or allogeneic hematopoietic stem cell transplantation (Auto-SCT/allo-SCT)as consolidation therapy in subjects with T lymphoblastic leukemia/Lymphoblastic lymphoma(T-ALL/LBL)who have achieved first comp…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for Drug-Resistant breast cancer: phase 3 trial launches
Disease control Recruiting nowThe study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.
Phase: PHASE3 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to outperform keytruda in head and neck cancer
Disease control Recruiting nowThis is a randomized, open-label, active-comparator-controlled, multi-regional, three-arm, phase 3 study comparing the efficacy and safety of ivonescimab in combination with ligufalimab to pembrolizumab and of ivonescimab alone to pembrolizumab as first-line treatment in patients…
Phase: PHASE3 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC